RT Journal Article
SR Electronic
T1 Patient-Reported Characteristics of Pernicious Anaemia: <em>A first step to initiate James Lind Alliance Priority Setting Partnership Driven Research</em>
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.30.24312837
DO 10.1101/2024.08.30.24312837
A1 Thain, Alfie
A1 Visser, Petra
A1 Hart, Kathryn
A1 Nexo, Ebba
A1 McCaddon, Andrew
A1 Hannibal, Luciana
A1 Wolffenbuttel, Bruce HR
A1 Green, Ralph
A1 Ward, Nicola
A1 Seage, Catherine Heidi
A1 Owen, Julian
A1 Burchell, Katrina
A1 Dib, Marie-Joe
A1 Ahmadi, Kourosh R
YR 2024
UL http://medrxiv.org/content/early/2024/08/31/2024.08.30.24312837.abstract
AB Objective Pernicious anaemia (PA) is characterised by vitamin B12 deficiency due to autoimmune-mediated loss of gastric parietal cells and intrinsic factor. The Pernicious Anaemia Society (PAS) identified 10 research priorities for PA through a James-Lind Alliance Priority Setting Partnership (JLA-PSP). This study aimed to survey PAS members to identify and characterise a cohort of patients to form a PA research repository.Methods An online survey was designed using SurveyMonkey, comprising 21 questions on diagnosis, comorbidities, family history, and management. The survey was sent to 3,482 PAS members (April-September 2022) via the PAS website and email.Results A total of 1,191 PAS members completed the survey. Among individuals with a probable (n=471) or suspected PA (n=500) diagnosis, 84% were UK-based, and 81% were female, with an age range of 23-93 years. Diagnosis was predominantly based on low serum B12 (50%), positive intrinsic factor (38%), and/or parietal cell autoantibodies (15%). Diagnostic delays were common, with 37% waiting ≥3 years for a diagnosis. Nearly half had one or more other autoimmune diseases. One-third reported having at least 2 and up to 7 family members with PA or other autoimmune diseases. Vitamin B12 treatment frequency varied widely, ranging from daily to 3-monthly injections.Conclusion This study highlights gaps in current diagnostic and management approaches for PA, paving the way for future work in line with the JLA-PSP research priorities. By characterising a cohort of PA patients and compiling baseline data, we provide a foundation for research to develop more effective diagnostic and management strategies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Univeristy of Surrey and the Pernicious Anaemia SocietyAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research Integrity and Governance Office of University of Surrey waived ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors